0.00Open0.00Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover283.98%IV5.05%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.3699Delta0.0507Gamma7.60Leverage Ratio-0.1964Theta-0.0018Rho-2.81Eff Leverage0.0099Vega
Keros Therapeutics Stock Discussion
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
Combining pure anti-Myostatin antibodies with Semaglutide was marginally effective in NHPs in preventing muscle loss. I believe that for that reason, $Scholar Rock (SRRK.US)$ and probably also $Biohaven (BHVN.US)$ are likely to disappoint.
Additionally blocking other ligands like Activin A dramatically improves body composition. That is what $Eli Lilly and Co (LLY.US)$ , $Keros Therapeutics (KROS.US)$ ...
No comment yet